Increased copy number of the TERT and TERC telomerase subunit genes in cancer cells

被引:153
作者
Cao, Ying [1 ,2 ]
Bryan, Tracy M. [2 ]
Reddel, Roger R. [1 ,2 ]
机构
[1] Childrens Med Res Inst, Canc Res Unit, Westmead, NSW 2145, Australia
[2] Univ Sydney, Sydney, NSW 2006, Australia
基金
英国惠康基金;
关键词
D O I
10.1111/j.1349-7006.2008.00815.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Telomerase is a ribonucleoprotein enzyme complex that adds telomeric repeats to the ends of chromosomes. The core telomerase components are the telomerase reverse transcriptase (TERT) catalytic subunit, and the telomerase RNA (TR) template subunit. In most cancers, telomerase is expressed at levels that are substantially higher than in normal cells. A known consequence of telomerase up-regulation which is considered to play a critical role in oncogenesis is maintenance of telomere length, and thus evasion by cancer cells of the normal limits on proliferation that are associated with the steady decrease in telomere length that accompanies proliferation of normal cells. It has also been suggested that telomerase up-regulation confers other advantages on cancer cells independent of its enzymatic activity. The mechanisms responsible for up-regulation of telomerase in cancer are incompletely understood. Here we review evidence suggesting that this frequently results from increased copy number of the genes encoding telomerase components. The TERT gene is located at human chromosome band 5p15.33, and the telomerase RNA component (TERC) gene that encodes TR is at 3q26.3. Chromosomal gains and gene amplifications involving chromosome arms 5p and 3q are among the most frequent in human tumors. Increased TERT and TERC gene dosage has been detected frequently in a variety of human cancers, and clonal evolution of cells with increased TERT or TERC copy number has been observed, suggesting a growth advantage in cells with increased TERT or TERC gene dosage.
引用
收藏
页码:1092 / 1099
页数:8
相关论文
共 67 条
[1]   Gene amplification in cancer [J].
Albertson, Donna G. .
TRENDS IN GENETICS, 2006, 22 (08) :447-455
[2]   Frequent gain of the human telomerase gene TERC at 3q26 in cervical adenocarcinomas [J].
Andersson, S. ;
Wallin, K-L ;
Hellstroem, A-C ;
Morrison, L. E. ;
Hjerpe, A. ;
Auer, G. ;
Ried, T. ;
Larsson, C. ;
Heselmeyer-Haddad, K. .
BRITISH JOURNAL OF CANCER, 2006, 95 (03) :331-338
[3]  
Avilion AA, 1996, CANCER RES, V56, P645
[4]   Telomerase beyond telomeres [J].
Blasco, MA .
NATURE REVIEWS CANCER, 2002, 2 (08) :627-632
[5]   Extension of life-span by introduction of telomerase into normal human cells [J].
Bodnar, AG ;
Ouellette, M ;
Frolkis, M ;
Holt, SE ;
Chiu, CP ;
Morin, GB ;
Harley, CB ;
Shay, JW ;
Lichtsteiner, S ;
Wright, WE .
SCIENCE, 1998, 279 (5349) :349-352
[6]   Mapping of the gene for the human telomerase reverse transcriptase, hTERT, to chromosome 5p15.33 by fluorescence in situ hybridization [J].
Bryce, LA ;
Morrison, N ;
Hoare, SF ;
Muir, S ;
Keith, WN .
NEOPLASIA, 2000, 2 (03) :197-201
[7]   Telomerase redefined: Integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity [J].
Cairney, C. J. ;
Keith, W. N. .
BIOCHIMIE, 2008, 90 (01) :13-23
[8]   TERT regulates cell survival independent of telomerase enzymatic activity [J].
Cao, Y ;
Li, H ;
Deb, S ;
Liu, JP .
ONCOGENE, 2002, 21 (20) :3130-3138
[9]  
CAO Y, 2008, IN PRESS CANC RES
[10]   Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo [J].
Chiang, YJ ;
Hemann, MT ;
Hathcock, KS ;
Tessarollo, L ;
Feigenbaum, L ;
Hahn, WC ;
Hodes, RJ .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (16) :7024-7031